Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

Autor: Suzanne Kafaja, Philip J. Clements, Holly Wilhalme, Chi-hong Tseng, Daniel E. Furst, Grace Hyun Kim, Jonathan Goldin, Elizabeth R. Volkmann, Michael D. Roth, Donald P. Tashkin, Dinesh Khanna, Ann Arbor, D. Khanna, Los Angeles, P. J. Clements, D. P. Tashkin, R. Elashoff, J. Goldin, M. Roth, D. Furst, K. Bulpitt, W.-L. J. Chung, S. Viasco, M. Sterz, L. Woolcock, X. Yan, J. Ho, S. Vasunilashorn, I. da Costa, J. R. Seibold, D. J. Riley, J. K. Amorosa, V. M. Hsu, D. A. McCloskey, J. E. Wilson, J. Varga, D. Schraufnagel, A. Wilbur, D. Lapota, S. Arami, P. Cole-Saffold, R. Simms, A. Theodore, P. Clarke, J. Korn, K. Tobin, M. Nuite, R. Silver, M. Bolster, C. Strange, S. Schabel, E. Smith, J. Arnold, K. Caldwell, M. Bonner, R. Wise, F. Wigley, B. White, L. Hummers, M. Bohlman, A. Polito, G. Leatherman, E. Forbes, M. Daniel, V. Steen, C. Read, C. Cooper, S. Wheaton, A. Carey, A. Ortiz, M. Mayes, E. Parsley, S. Oldham, T. Filemon, S. Jordan, M. Perry, null K. Connolly, J. Golden, P. Wolters, R. Webb, J. Davis, C. Antolos, C. Maynetto, B. Fessler, M. Olman, C. Sanders, L. Heck, T. Parkhill, N. Rothfield, M. Metersky, R. Cobb, M. Aberles, F. Ingenito, E. Breen, K. Mubarak, J. L. Granda, J. Silva, Z. Injic, R. Alexander, S. Springmeyer, S. Kirkland, J. Molitor, R. Hinke, A. Mondt, T. Thompson, S. Rounds, M. Weinstein, B. Thompson, H. Paulus, S. Levy, D. Martin, E. Kissin, F. Y. Cheong, G. Marlis, J. Mason-Berry, P. Saffold, M. Rodriguez, L. Guzman, J. Brook, G. Ibrahim, K. Largaespada, C. Fridley, M. Zulmastashvili, A. Manu, S. Moore, F. N. Hant, K. Gibson, M. Morrison, H. Donnelly, C. Marlin, J. Gangar, A. Eller, D. Leong, M. Lalosh, J. Obata, D. Franklin, E. Schiopu, M. Benedict-Blue, V. Leone, J. Shaw, F. Tan, J. Anderson, A. Saulino, P. Carey, M. Esplin, P. Carlson

Publikováno v: American journal of respiratory and critical care medicine. 197(5)

Rationale: FVC percent predicted (FVC%) is the primary outcome measure in clinical trials of systemic sclerosis interstitial lung disease. For interpretation of change in the FVC% over time, it is important to define whether these changes are clinica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85f4196559588eeaa282cfc49e0fb9be
https://pubmed.ncbi.nlm.nih.gov/29186664